Multi-Criteria Decision Analysis (MCDA) as an alternative decision making framework for health technology assessment in Canada

Decision-making frameworks for Health Technology Assessment (HTA) have become a major topic in developed nations in recent years. Indeed, the quest for more rational and transparent HTA decision led many jurisdictions to investigate the use of Multi-Criteria Decision Analysis (MCDA) as an alternative decision-making framework. In Canada, the development of a MCDA framework for HTA decision-making is in its infancy. Indeed, to our knowledge, only one MCDA framework has been proposed and tested in the country.

Investigation of adverse effects and healing factor properties of a novel formulation from Blue-O

The appearance of multidrug resistance of pathogens is challenging the researcher and industrial communities to develop more efficacious antimicrobial treatments. Blue-O Technology Incorporation (Blue-O Tech) has developed a novel formulation of medicine that accelerates the wound healing, while having an excellent antimicrobial strength over a broad spectrum of pathogens. The objectives of this study are to evaluate the cytotoxic effects, the immunological response, and the healing properties of this novel medicine prior to its marketing and commercialization.

Integration of microwave technology to microfluidic systems for high throughput combinatorial tests and lab-on-a-chip applications

The high throughput combinatorial testing for pharmaceutical applications requires fast methods for manipulating droplets in microfluidic systems. In this project, a microwave platform will be designed and employed for fast droplet heating, identification and detection. The use of extremely confined microwave energy makes heating, detecting, and identifying droplets possible. With the new platform it will be possible to control the temperature of each droplet separately.

Development and optimization of a polymer-lipiu urug ueiivCi y formulation for the peri-operative treatment of ovarian cancer

The goal of the current research is to design an injectable polymer-lipid (Pol.i) formulation to treat ovarian cancer. The PoLi drug delivery system is a hiocompatible and biodegradable, physically cross-linked gel that has the potential to provide dramatic improvements in the treatment of ovarian cancer. It is formulated as an injectable gel (all components are safe for humans) which is then loaaded with active chemotherapy drugs such as the commercially available paclitaxel.

Dry powder coating of solid pharmaceutical dosages

Solid pharmaceutical dosage forms such as tablets and beads used in capsules are currently coated by liquid coating technology, which incurs high environmental risk and high capital and operation costs. Prof. Zhu's research group has developed an ultratine powder coating technology for the auto industry. Our previous studies have shown that the same technology can also be extended for pharmaceutical solid dosage forms. So far, first success in the new coating technology has been achieved and several coating systems have been developed using acceptable formulations.